HSP90B1 and glioblastoma: Because of the special immune microenvironment of the human brain, gp96 immunotherapy for intracranial malignancy was developed relatively late, and information on 7 clinical trials of glioblastoma treatment can be accessed at https://clinicaltrials.gov/ (Table 1).